<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380324</url>
  </required_header>
  <id_info>
    <org_study_id>17237</org_study_id>
    <secondary_id>J1P-MC-KFAA</secondary_id>
    <secondary_id>16-358-01</secondary_id>
    <nct_id>NCT04380324</nct_id>
  </id_info>
  <brief_title>A Study of NKTR-358 (LY3471851) in Healthy Participants</brief_title>
  <official_title>A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Dose of NKTR-358 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nektar Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and tolerability of a study drug
      known as LY3471851 in healthy participants. The study will last about 50 days for each
      participant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LY3471851 is a potential first-in-class therapeutic that may address an underlying immune
      system imbalance in people with many autoimmune conditions. It targets the interleukin (IL-2)
      receptor complex in the body in order to stimulate proliferation of inhibitory immune cells
      known as regulatory T cells. By activating these cells, LY3471851 may act to bring the immune
      system back into balance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2017</start_date>
  <completion_date type="Actual">January 20, 2019</completion_date>
  <primary_completion_date type="Actual">January 20, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline up to Day 50</time_frame>
    <description>Number of Participants with One or More SAEs Considered by the Investigator to be Related to Study Drug Administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3471851</measure>
    <time_frame>Predose on Day 1 through Day 50</time_frame>
    <description>PK: Cmax of LY3471851</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of LY3471851</measure>
    <time_frame>Predose on Day 1 through Day 50</time_frame>
    <description>PK: (AUC[0-inf]) of LY3471851</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): Mean Change from Baseline in Regulatory T cells (Tregs)</measure>
    <time_frame>Predose on Day 1 through Day 50</time_frame>
    <description>PD: Mean change from baseline in Tregs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Change from Baseline in Treg Activation Markers</measure>
    <time_frame>Predose on Day 1 through Day 50</time_frame>
    <description>PD: Treg activation markers include: Cytokine levels, conventional CD4+ and CD8+ Tcells, and natural killer (NK) cells</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3471851</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants in each cohort will receive single subcutaneous (SC) doses of LY3471851.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy participants in each cohort will receive the placebo comparator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3471851</intervention_name>
    <description>LY3471851 drug product is a sterile liquid for SC injection that may be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.</description>
    <arm_group_label>LY3471851</arm_group_label>
    <other_name>NKTR-358</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo dosing solution is 0.9% sodium chloride for injection (USP).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy males and females, as determined by medical history and physical
             examination

          -  Have a body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg/mÂ²)

        Exclusion Criteria:

          -  Previous or current autoimmune disease/disorder

          -  Current active bacterial, viral, or fungal infection

          -  Administration of an inactivated vaccine within two weeks of study drug administration
             or live attenuated vaccine within 90 days of dosing .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

